Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JPLSG-AML-D24 risk-stratified azacitidine-based chemotherapy study in pediatric myeloid leukemia with Down syndrome
jRCTs041250031Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine, cytarabine, etoposide and pirarubicin in myeloid leukemia associated with Down syndrome (ML-DS) (4 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 3-year event-free survival. Started Jun 2025; status: recruiting.
02
Drugs
azacitidinecytarabineetoposidepirarubicin
03
Conditions
myeloid leukemia associated with Down syndrome (ML-DS)
Beyond the preview
Go deeper on jRCTs041250031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250031.